Ridiculous? The focus is solely on the uplist. A
Post# of 30027
Posted On: 09/22/2015 11:30:38 PM
Ridiculous? The focus is solely on the uplist. Agreed this was never the plan, but you have to adjust on the fly.
The company is toast without the uplist and you have to do, what you have to do.
The whole plan is based on GC's statements that you have to get to NASDAQ to reach the institutional investors that desperately want in but who are prohibited from doing so until the company is on NASDAQ. If that is not true, we are done. If it is true, you take your lumps and raise money at these horrid price. Ridiculous? No. Painful? Yes.
The company is toast without the uplist and you have to do, what you have to do.
The whole plan is based on GC's statements that you have to get to NASDAQ to reach the institutional investors that desperately want in but who are prohibited from doing so until the company is on NASDAQ. If that is not true, we are done. If it is true, you take your lumps and raise money at these horrid price. Ridiculous? No. Painful? Yes.
Quote:
In all due respect these scenarios are ridiculous. The dilution is needed for burn rate, trials, everything pretty much. An up list , let alone an uplist from strength, is not possible from our current financial situation. The plan was to ipo from shelf however that's absurd I mean literally absurd from this pps! Horrible for all shareholders including management who have shares. There was never a plan to tap shelf and raise at 1.44. Nasdaq at 1.44 with no funds just seems silly, I'd assume committee would feel a dlist would be in cards with continued dilution guaranteed. They need to ipo to raise and not from 1.44 lol
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼